Cannabis Deal Tracker: Investment and M&A Activity in the Cannabis Industry May 3rd - May 7th, 2021
May 12, 2021 (Investorideas.com Newswire) KEY INSIGHTS & TAKEAWAYS
- Transactional Activity: There was one less capital raise and $135.7 million higher volume this week than in the prior week. Compared to the same week last year, four fewer transactions closed with a $278.4 million higher volume. The average deal size was $64.6 million this week vs. $15.8 million in the same week last year.
- Issuance bounced back this week with $316 million of total capital raised, but 2021 now trails 2019 in both equity and debt capital raised.
- The price of our basket of 25 cannabis stocks was down 1.5% this week as disappointing earnings reports from Canadian LPs weigh on market.
- Largest Equity Raise: On May 3rd, 2021, Hydrofarm Holdings (Nasdaq: HYFM), a leading supplier of hydroponics equipment and supplies for controlled environment agriculture, closed an upsized US$326 million underwritten public offering.
- 5.527 million shares at $59 per share.
- Shares were sold at a slight 4.3% discount from the price on the announcement date.
- The sale imputes a market cap of $2.98 billion. The EV / annualized 2021 revenue multiple was 7.4x, a significant discount to the 9.9x median multiple of the four agriculture technology companies we track with more than $200 million market cap
- Hydrofarm has excellent liquidity and low leverage, suggesting it could do debt financing if it chose to do one
- Proceeds will be used for acquisitions, working capital, and other general corporate purposes.
- 2nd Largest Equity Raise: On May 7th, Ascend Wellness completed a $92 million IPO.
- 11.50 million shares at $8 per share.
- The imputed market cap is $413 million. EV / annualized revenues based on the 4th quarter of 2020 was 8.7x, a modest discount to the median multiple of 9.7x we calculate for the 11 cultivation and retail companies we track with over $1billion in market cap.
- Proceeds will be used to fund the expansion of cultivation and processing facilities, future acquisitions, fund working capital, and general corporate purposes.
- The loan is secured by first liens on the company's New Jersey real estate and other commercial security interests
- Loan terms were not disclosed.
MERGERS & ACQUISITIONS
- Transactional Activity: Eighteen M&A transactions were completed this week, compared to two in the prior-year period. We have tracked 116 transactions YTD in 2021, compared to 28 in the same period last year. Public companies were the buyers in 84% of 2021 deals YTD compared to 89% in 2020. This week was a new record in terms of the number of YTD deals with US targets. Overall deal totals continue to lag those of 2019 because of the pullback of Canadian targeted transactions.
- This week saw the closing of the two largest cannabis-related deals ever completed with the $7.2 billion acquisition of GW Pharma by Jass Pharma and the $4.5 billion merger of Tilray and Aphria. And the ink had hardly dried on those two before the blockbuster Trulieve/Harvest deal got announced. Like, the Tilray/Aphria deal, we think Trulieve/Harvest makes excellent strategic sense. Harvest was never going to be a contender in Florida, and even with Trulieve's aggressive moves in Pennsylvania, the market saw its pace of diversification as too slow.
- Largest M&A Transaction: The May 4th $7.2 billion acquisition of GW Pharmaceuticals (Nasdaq: GWPH) by Jazz Pharmaceuticals (Nasdaq: JAZZ) is the largest cannabis industry acquisition ever completed.
- Consideration consists of $200 in cash (total of $6.52B) and $20 in stock ($652M) for each GW share.
- The consideration represents a premium of about 50% over the pre-announcement price of GW.
- The implied enterprise value represents 12.0x annualized GW revenue.
- GW broke new ground when its drug Epidiiolx, a child epilepsy medication that contains cannabidiol (CBD), was the first cannabis-related drug to be approved for use by the FDA.
- 2nd Largest M&A Transaction: On May 3rd, 2021, Tilray (Nasdaq: TLRY) and Aphria (Nasdaq: APHA) closed their $4.5 billion merger.
- Each of Tilray's' outstanding 317 million shares received .8381 Tilray shares valued at $17.02 per share for total consideration of $4.5 billion.
- The consideration represents a 9.3x multiple of Aphria's annualized revenues.
- The transaction creates the world's largest cannabis company by revenues.
- Annual synergies of $81 million are expected to be achieved within 18 months
- Aphria shareholders will control approximately 62% of the combined company.
- Although the deal makes sense on its own by rationalizing the cost structures of the two companies, the fundamental logic is in anticipation of a legalized US. Tilray's Manitoba Harvest and Aphria's Sweetwater craft brewing business are meant to be launching pads into the US, but legalization may take longer than expected, while price compression in Canada is now.
- Public vs. Private: Seventeen of this week's eighteen acquisitions were made by public companies.
- M&A by Sector: Ten of this week's buyers came from the Cultivation & Retail sector, three from Biotech/Pharma, two from Software/Media, and one each from Hemp, Agriculture Technology, and Infused Products & Extracts.
The Viridian Cannabis Deal Tracker is a proprietary information service that monitors capital raise and M&Amp;Amp;A activity in the legal cannabis and hemp industry. Each week the Tracker aggregates and analyzed all closed deals and segments each according to key metrics:
- Industry Sector (One of 12 sectors, from Cultivation to Brands)
- Dollar value of the transaction
- Region in which the deal occurred (Country or U.S. State)
- Status of the company announcing the transaction (Public vs. Private)
- Deal structure (Equity vs. Debt)
- Key deal terms (Pricing and Valuation)
The Viridian Cannabis Deal Tracker provides the market intelligence that cannabis companies, investors, and acquirers utilize to make informed decisions regarding capital allocation and M&Amp;Amp;Amp;A strategy.
Since its inception in 2015, the Viridian Cannabis Deal Tracker has tracked and analyzed more than 2,500 capital raises and 1,000 M&Amp;Amp;Amp;A transactions totaling over $45 billion in aggregate value.
*Copyright © 2021 by Viridian Capital Advisors
All rights reserved. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the publisher, except in the case of brief quotations embodied in critical reviews and certain other noncommercial uses permitted by copyright law. For permission requests, write to the publisher. No part of this material may be (I) copied, photocopied, or duplicated in any form, by any means, or (II) redistributed without Viridian's prior written consent.
The information contained herein is for informational purposes and is not intended as a research report. It should not be construed as Viridian recommending investment in cannabis companies or as a solicitation to buy or sell any security or engage in a particular investment strategy. Investment in cannabis companies entails substantial risk. Before acting on any information, you should consider whether it is suitable for your particular circumstances and consult all available material, and, if necessary, seek professional advice.
Viridian Capital Advisors and its affiliates, as well as their respective partners, directors, shareholders, and employees, may have a position in the securities mentioned herein or may make purchases and/or sales from time to time. Viridian Capital Advisors, through broker-dealer services provided by Bradley Woods & Co. Ltd., (Member FINRA/SIPC), may act, or may have acted in the past, as a financial advisor to certain companies mentioned herein and may receive, or may have received, a remuneration for their services from those companies.
The above information whether in part or in its entirety neither constitutes an offer nor makes any recommendation to buy or sell any securities.
About Viridian Capital Advisors, LLC
Viridian Capital Advisors (www.viridianca.com) is a financial and strategic advisory firm dedicated to the cannabis market. We are a data- and market intelligence-driven firm that provides investment, M&Amp;Amp;A, corporate development, and investor relations services to emerging growth companies and qualified investors in the cannabis sector. Our banking practice, through broker-dealer Bradley Woods & Co. Ltd. (Member FINRA/SIPC), provides capital and M&Amp;Amp;A services to fund the growth of our clients, while our advisory practice helps to position and build their businesses. Our team's decades of high level operating and transactional experience on Wall Street in a variety of emerging sectors, allows Viridian to provide comprehensive strategic and financial solutions that assist cannabis enterprises in realizing their full potential.
Marijuana remains illegal under federal law. The federal government does not recognize marijuana to have any medicinal value. Marijuana cultivation, possession, consumption, sales, and distribution are illegal under federal laws and also certain state laws. Investors in cannabis may be subject to law enforcement actions. Please note that there are differences in marijuana laws from one state, county, or city to another. Furthermore there are substantial risks associated with investing in cannabis companies, including, without limitation, changes in applicable laws, rules, and regulations, risks associated with the economic environment, the financing markets, and risks associated with a company's ability to execute on its business plan.
Viridian Capital Advisors, LLC
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Sign up for free stock news alerts at Investorideas.com